A 15-year-old girl with no pulmonary symptoms developed acute liver failure associated with COVID-19; liver biopsy showed submassive necrosis with in situ-hybridization and immunohistochemistry confirming replicating SARS-CoV-2 RNA in hepatocytes.
JPGN Reports · 14 authors, 7 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
A 15-year-old girl with no pulmonary symptoms developed acute liver failure associated with COVID-19; liver biopsy showed submassive necrosis with in situ-hybridization and immunohistochemistry confirming replicating SARS-CoV-2 RNA in hepatocytes.
A 15-year-old girl presented with anosmia, ageusia, nausea, vomiting, and no pulmonary symptoms, with confirmed SARS-CoV-2 exposure. She developed ALF on hospital day 2, and extensive etiologic testing was unrevealing. Treatment included vitamin K, broad-spectrum antibiotics, lactulose, rifaximin, dexamethasone, CRRT for hyperammonemia, N-acetyl cysteine, and compassionate-use casirivimab/imdevimab on HD5. She improved on HD6 and was extubated on HD7. Liver biopsy on HD15 showed acute hepatitis with submassive centrilobular necrosis. In situ-hybridization detected replicating SARS-CoV-2 RNA in hepatocytes, and immunostaining confirmed nucleocapsid protein expression. She was discharged on HD16 with normal liver tests at 5 months. The authors noted a temporal association between monoclonal antibody administration and clinical improvement but could not establish causality.